AB5038P
Anti-Synuclein α Antibody
Chemicon®, from rabbit
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Anti-NACP, Anti-PARK4, Anti-PD1
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... SNCA(6622)
General description
alpha -Synuclein is a small (140-amino acid) cytoplasmic protein of unclear function that is enriched in presynaptic terminals and is the precursor protein of a nonamyloid beta component of senile plaques in Alzeheimer′s Disease (AD). alpha -Synuclein is located predominantly in the presynaptic nerve terminals in the brain but is also found in low concentrations in all tissues except liver. Recent studies have shown that abnormal aggregation and accumulation of synaptic proteins, including alpha-Synuclein might be associated with plaque formation in AD and seems to be a major component of Lewy bodies in dementia with Lewy bodies (DLB). It has also been identified in the Glial Cytoplasmic Inclusions (GCIs) found in Multiple System Atrophy (MSA).
Specificity
Recognizes Alpha-synuclein. The immunizing peptide was chosen to reduce cross-reactivity of AB5038 with beta-synuclein to a minimum. Immunohistochemical and Western blot analysis of human brain indicates a high level of specificity.
Immunogen
Human alpha-synuclein residues 111-131 coupled to KLH. The peptide sequence is N-GILEDMPVDPDNEAYEMPSEEC-C. This peptide is available for use in blocking studies (Cat. No. AG239).
Application
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
This Anti-Synuclein Antibody, α is validated for use in IH(P), WB for the detection of Synuclein.
Western blot: 1:1000-1:2000
Immunohistochemistry: 1:1000-1:2000 on paraffin sections, 1:4000-1:12,000 on frozen sections..
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 1:1000-1:2000 on paraffin sections, 1:4000-1:12,000 on frozen sections..
Optimal working dilutions must be determined by end user.
Target description
14-19 kDa
Linkage
Replaces: 04-1053
Physical form
Affinity Purified immunoglobulin. Lyophilized, no preservatives. Reconstitute with 20 μL of sterile distilled water. Centrifuge to remove any residue.
ImmunoAffinity Purified
Storage and Stability
Maintain at -20 in undiluted aliquots for up to 12 months after date of receipt. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. Glycerol (1:1) can be added for additional stability.
Analysis Note
Control
Brain tissue
Brain tissue
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
recommended
Product No.
Description
Pricing
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Juan C Vizcarra et al.
Free neuropathology, 4 (2023-06-22)
The collection of post-mortem brain tissue has been a core function of the Alzheimer Disease Research Center's (ADRCs) network located within the United States since its inception. Individual brain banks and centers follow detailed protocols to record, store, and manage
Christopher Gibbons et al.
Neurology, 100(15), e1529-e1539 (2023-01-20)
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the nervous system. Clinical features include autonomic and motor dysfunction, which overlap with those of Parkinson disease (PD), particularly at early disease stages.
Dominique Bétemps et al.
Acta neuropathologica communications, 2, 29-29 (2014-03-15)
The accumulation of misfolded proteins appears as a fundamental pathogenic process in human neurodegenerative diseases. In the case of synucleinopathies such as Parkinson's disease (PD) or dementia with Lewy bodies (DLB), the intraneuronal deposition of aggregated alpha-synuclein (αS) is a
Michael Helwig et al.
Brain : a journal of neurology, 139(Pt 3), 856-870 (2016-01-01)
Aggregation and neuron-to-neuron transmission are attributes of α-synuclein relevant to its pathogenetic role in human synucleinopathies such as Parkinson's disease. Intraparenchymal injections of fibrillar α-synuclein trigger widespread propagation of amyloidogenic protein species via mechanisms that require expression of endogenous α-synuclein
Raffaella Rusconi et al.
Aging cell, 17(2) (2018-02-01)
Increased expression of α-synuclein can initiate its long-distance brain transfer, representing a potential mechanism for pathology spreading in age-related synucleinopathies, such as Parkinson's disease. In this study, the effects of overexpression-induced α-synuclein transfer were assessed over a 1-year period after
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service